{"content":"<li class=\"n-box-item date-title\" data-end=\"1482382799\" data-start=\"1482296400\" data-txt=\"Sunday, December 22, 2019\">Wednesday, December 21, 2016</li><li class=\"n-box-item sa-box-item\" data-id=\"3232116\" data-ts=\"1482364212\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNSL\" target=\"_blank\">CNSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232116-consolidated-communications-sets-new-acquisition-loan-in-fairpoint-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consolidated Communications sets new acquisition loan in FairPoint deal</a></h4><ul>   <li>Consolidated Communications (<a href=\"https://seekingalpha.com/symbol/CNSL\" title=\"Consolidated Communications Holdings, Inc.\">CNSL</a> <font color=\"red\">-2%</font>) has set a new term loan for its <a href=\"https://seekingalpha.com/news/3228484-consolidated-communications-acquires-fairpoint-communications\" target=\"_blank\">$1.5B takeover</a> of FairPoint Communications (<a href=\"https://seekingalpha.com/symbol/FRP\" title=\"FairPoint Communications, Inc.\">FRP</a> <font color=\"red\">-1.6%</font>).</li>    <li>The new deal is essentially a tack-on to its existing facility, set at Libor plus 3% and the greater of a 1% Libor floor and the three-month adjusted Libor.</li>    <li>Previously secured debt is being used along with cash on hand to repay some FairPoint debt and pay fees; the new loan provides for a single draw of up to $935M at closing time.</li>    <li>The company wanted to be opportunistic to address new financing soon after announcing the deal, and \"We are extremely pleased with the outcome and we have significantly de-risked our capital structure by going to market now,\" says CFO Steve Childers.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232116\" data-linked=\"Consolidated Communications sets new acquisition loan in FairPoint deal\" data-tweet=\"$CNSL $CNSL $FRP - Consolidated Communications sets new acquisition loan in FairPoint deal https://seekingalpha.com/news/3232116-consolidated-communications-sets-new-acquisition-loan-in-fairpoint-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3232116-consolidated-communications-sets-new-acquisition-loan-in-fairpoint-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232105\" data-ts=\"1482360859\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLUU\" target=\"_blank\">GLUU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232105-glu-mobile-buys-maker-of-quizup-adds-ceo-to-board\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Glu Mobile buys maker of &#39;QuizUp,&#39; adds CEO to board</a></h4><ul>   <li>Glu Mobile (<a href=\"https://seekingalpha.com/symbol/GLUU\" title=\"Glu Mobile Inc.\">GLUU</a> <font color=\"red\">-4.5%</font>) reports settling a few recent affairs in a new <a href=\"https://seekingalpha.com/filing/3332307\" target=\"_blank\">SEC filing</a>, including an acquisition.</li>    <li>It purchased the assets of Reykjavik-based Plain Vanilla, the maker of mobile game <i>QuizUp.</i> Glu paid $1.2M in cash and also forgave $7.5M in convertible promissory notes of Plain Vanilla that it held, contingent on <i>QuizUp</i> going to the Apple/Android app stores under Glu's name.</li>    <li>The company also expanded the board to nine members from its previous eight, to make room for new CEO Nick Earl. Earl becomes a Class II director assigned to the Strategy Committee.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232105\" data-linked=\"Glu Mobile buys maker of &#39;QuizUp,&#39; adds CEO to board\" data-tweet=\"$GLUU - Glu Mobile buys maker of &#39;QuizUp,&#39; adds CEO to board https://seekingalpha.com/news/3232105-glu-mobile-buys-maker-of-quizup-adds-ceo-to-board?source=tweet\" data-url=\"https://seekingalpha.com/news/3232105-glu-mobile-buys-maker-of-quizup-adds-ceo-to-board\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232103\" data-ts=\"1482359847\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232103-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/CVRR' title='CVR Refining, LP'>CVRR</a> <font color='green'>+11.0%</font>. <a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a> <font color='green'>+9.5%</font>. <a href='https://seekingalpha.com/symbol/CVI' title='CVR Energy, Inc.'>CVI</a> <font color='green'>+4.9%</font>. <a href='https://seekingalpha.com/symbol/PBF' title='PBF Energy'>PBF</a> <font color='green'>+3.5%</font>. <a href='https://seekingalpha.com/symbol/PSTG' title='Pure Storage'>PSTG</a> <font color='green'>+2.3%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/RHT' title='Red Hat, Inc.'>RHT</a> <font color='red'>-13.0%</font>. <a href='https://seekingalpha.com/symbol/MLHR' title='Herman Miller, Inc.'>MLHR</a> <font color='red'>-6.3%</font>. <a href='https://seekingalpha.com/symbol/CAMP' title='CalAmp Corp.'>CAMP</a> <font color='red'>-5.9%</font>. <a href='https://seekingalpha.com/symbol/BBBY' title='Bed Bath & Beyond Inc.'>BBBY</a> <font color='red'>-2.0%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232103\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$CVRR $MU $CVI - After Hours Gainers / Losers https://seekingalpha.com/news/3232103-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3232103-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232092\" data-ts=\"1482357154\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RHT\" target=\"_blank\">RHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232092-red-hatminus-13_5-q3-mixed-cfo-departs-guidance-light\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Red Hat -13.5%; Q3 mixed, CFO departs, guidance light</a></h4><ul>\n<li>\n<strong><a href=\"https://seekingalpha.com/news/3232078-red-hat-beats-0_03-misses-revenue\" target=\"_blank\">Results</a></strong> \u2013 revenue $615.26M (+17.5% Y/Y, <font color=\"red\">$2.76M below estimates</font>), EPS $0.61 (<font color=\"green\">$0.03 above estimates</font>), operating income $143M (+16% Y/Y), operating margin 23.3%, net income $111M (vs. $89M Y/Y), operating cash flow $136M (-8% Y/Y), cash, cash equivalents and investments $2B, remaining repurchase authorization balance $775M, deferred revenue $1.7B (+15% Y/Y),</li>\n<li>\n<strong>Segment revenues</strong> \u2013 Subscriptions $543.318M (vs. $457.488M Y/Y), Training and Services $71.942M (vs. $66.092M Y/Y)</li>\n<li>\n<strong>Other developments</strong> \u2013 CFO Frank Calderoni departing (<a href=\"https://www.sec.gov/Archives/edgar/data/1087423/000119312516800522/d317052dex991.htm\" target=\"_blank\">resignation letter</a>), effective late January, 2017, for a CEO role elsewhere. Current finance and accounting VP Eric Shander to be appointed acting CFO pending permanent replacement.</li>\n<li>\n<strong>Q4 projections</strong> \u2013 revenue $614M-$622M (<a href=\"https://finance.yahoo.com/quote/RHT/analysts?p=RHT\" target=\"_blank\">consensus $637.44M</a>), EPS $0.61 (consensus $0.61), operating margin 24%</li>\n<li>\n<strong>FY 2017 projections</strong> \u2013 revenue $2.397B-$2.405B (consensus $2.42B), EPS $2.27 (consensus $2.22), operating margin 23%, operating cash flow $770M-$785M</li>\n<li>Red Hat (NYSE:<a href=\"https://seekingalpha.com/symbol/RHT\" title=\"Red Hat, Inc.\">RHT</a>) president and CEO Jim Whitehurst: \"Enterprise and service provider customers continue to adopt a hybrid cloud strategy for developing, deploying and managing the life-cycle of their critical applications. Red Hat is uniquely positioned to address this need. In aggregate, customers utilizing our cloud-enabling technologies either on-premise or in the public cloud are spending more with Red Hat than customers that have not yet embraced our cloud-enabling technologies.\"</li>\n<li><a href=\"http://78449.choruscall.com/dataconf/productusers/rht/mediaframe/17721/indexr.html\" target=\"_blank\">Conference call</a></li>\n<li><a href=\"https://seekingalpha.com/filing/3332313\" target=\"_blank\">8-K</a></li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232092\" data-linked=\"Red Hat -13.5%; Q3 mixed, CFO departs, guidance light\" data-tweet=\"$RHT - Red Hat -13.5%; Q3 mixed, CFO departs, guidance light https://seekingalpha.com/news/3232092-red-hatminus-13_5-q3-mixed-cfo-departs-guidance-light?source=tweet\" data-url=\"https://seekingalpha.com/news/3232092-red-hatminus-13_5-q3-mixed-cfo-departs-guidance-light\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232091\" data-ts=\"1482356615\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIA\" target=\"_blank\">VIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232091-longtime-viacom-exec-herzog-to-leave-company\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Longtime Viacom exec Herzog to leave company</a></h4><ul>   <li>Another departure at Viacom (<a href=\"https://seekingalpha.com/symbol/VIA\" title=\"Viacom Inc.\">VIA</a> <font color=\"green\">+1.7%</font>, <a href=\"https://seekingalpha.com/symbol/VIAB\" title=\"Viacom Inc.\">VIAB</a> <font color=\"green\">+1.8%</font>) as longtime executive <a href=\"http://www.reuters.com/article/us-viacom-executives-herzog-idUSKBN14A20E\" target=\"_blank\">Doug Herzog is set to exit</a> next month, Reuters reports.</li>    <li>Herzog had oversight of Comedy Central and MTV -- two networks that have struggled with ratings of late, though Herzog helped develop past hits including <i>The Real World</i> and <i>The Daily Show.</i>\n</li>    <li>Recently named CEO Bob Bakish will take over the brands in Herzog's Music and Entertainment Group.</li>    <li>Herzog had begun his Viacom career as president of MTV Productions in 1984.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232091\" data-linked=\"Longtime Viacom exec Herzog to leave company\" data-tweet=\"$VIA $VIA $VIAB - Longtime Viacom exec Herzog to leave company https://seekingalpha.com/news/3232091-longtime-viacom-exec-herzog-to-leave-company?source=tweet\" data-url=\"https://seekingalpha.com/news/3232091-longtime-viacom-exec-herzog-to-leave-company\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232079\" data-ts=\"1482355358\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232079-micron-technologyplus-7_4-q1-over-estimates-outlook-robust\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron Technology +7.4%; Q1 over estimates, outlook robust</a></h4><ul>\n<li>\n<strong><a href=\"https://seekingalpha.com/news/3232066-micron-technology-beats-0_04-beats-revenue\" target=\"_blank\">Results</a></strong> \u2013 revenue $3.97B (+18.5% Y/Y, +23% Q/Q, <font color=\"green\">$20M above estimates</font>), EPS $0.32 (<font color=\"green\">$0.04 above estimates</font>), net income $335M (vs. $299M Y/Y), investments in capital expenditures (net of amounts funded by partners) $1.18B, cash and marketable investments $4.32B</li>\n<li>\n<strong>Highlights</strong> \u2013 DRAM sales volume +18% Q/Q, DRAM average selling prices +5%, NAND sales volume +26%</li>\n<li>\n<a href=\"http://files.shareholder.com/downloads/ABEA-45YXOQ/3485027963x0x921916/F658CB0F-855C-4EF8-91AC-FE40E70D51AF/FQ1-2017_Earnings_Slides.pdf\" target=\"_blank\">Q2 projections</a> \u2013 revenue $4.35B-$4.70B (<a href=\"https://finance.yahoo.com/quote/MU/analysts?p=MU\" target=\"_blank\">consensus $3.91B</a>), EPS $0.58-$0.68 (consensus $0.39), gross margin 31%-34%, operating expenses $590M-$640M, operating income $800M-$900M</li>\n<li>Micron Technology (NASDAQ:<a href=\"https://seekingalpha.com/symbol/MU\" title=\"Micron Technology Inc.\">MU</a>) CEO Mark Durcan: \"Positive market momentum, driven by favorable demand trends and limited industry supply, produced solid results for our first quarter. We continue to make significant progress on our key technology and product initiatives, and we are pleased to have closed the Inotera acquisition on December 6, 2016, which we expect to further improve Micron\u2019s strategic position and financial results.\"</li>\n<li><a href=\"http://edge.media-server.com/m/p/wry9x8gg\" target=\"_blank\">Conference call</a></li>\n<li><a href=\"https://seekingalpha.com/filing/3332174\" target=\"_blank\">8-K</a></li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232079\" data-linked=\"Micron Technology +7.4%; Q1 over estimates, outlook robust\" data-tweet=\"$MU - Micron Technology +7.4%; Q1 over estimates, outlook robust https://seekingalpha.com/news/3232079-micron-technologyplus-7_4-q1-over-estimates-outlook-robust?source=tweet\" data-url=\"https://seekingalpha.com/news/3232079-micron-technologyplus-7_4-q1-over-estimates-outlook-robust\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232075\" data-ts=\"1482355193\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NH\" target=\"_blank\">NH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232075-nanthealth-prices-convertible-debt-offering-shares-up-5-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NantHealth prices convertible debt offering; shares up 5% after hours</a></h4><ul>\n<li>NantHealth (NASDAQ:<a href=\"https://seekingalpha.com/symbol/NH\" title=\"NantHealth\">NH</a>) perks up <font color=\"green\">5%</font> after hours, albeit on only 696 shares, on the heels of its announcement of pricing and terms of its $100M private offering of 5.50% Convertible Senior Notes due 2021.</li>\n<li>The initial conversion rate of the unsecured Notes will be 82.3893 common shares per $1,000 principal amount, implying a share price of $12.14.</li>\n<li>Net proceeds should be ~$96.2M (or $110.7M if initial purchasers fully exercise their option to buy an additional $15M of the Notes). Closing date is December 21.</li>\n<li>Today's close was $11.69.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232075\" data-linked=\"NantHealth prices convertible debt offering; shares up 5% after hours\" data-tweet=\"$NH - NantHealth prices convertible debt offering; shares up 5% after hours https://seekingalpha.com/news/3232075-nanthealth-prices-convertible-debt-offering-shares-up-5-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3232075-nanthealth-prices-convertible-debt-offering-shares-up-5-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232060\" data-ts=\"1482352924\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMY-OLD\" target=\"_blank\">IMMY-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232060-imprimis-pharma-teams-up-focusscript-in-specialized-pharmacy-compounds-shares-up-20\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Imprimis Pharma teams up with FocusScript in specialized pharmacy compounds;  shares up 20%</a></h4><ul>\n<li>Thinly traded nano cap Imprimis Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/IMMY-OLD\" title=\"Imprimis Pharmaceuticals, Inc.\">IMMY-OLD</a> <font color=\"green\">+19.9%</font>) jumps on a 4x surge in volume, albeit on turnover of only 320K shares, in response to its announcement of the joint launch of the Correct Compound program with FocusScript, LLC, an independent specialized pharmacy claims management firm.</li>\n<li>Correct Compound is a specialized compound pharmacy care solution that provides a customized formulary via Focus' CDF-Logic program with low-cost alternative compounded medications through Imprimis Cares. The process is tied together by a comprehensive billing and claims management platform.</li>\n<li>Focus will manage and process Correct Compound claims across its preferred network of over 200 compounding pharmacies.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232060\" data-linked=\"Imprimis Pharma teams up with FocusScript in specialized pharmacy compounds;  shares up 20%\" data-tweet=\"$IMMY-OLD - Imprimis Pharma teams up with FocusScript in specialized pharmacy compounds; shares up 20% https://seekingalpha.com/news/3232060-imprimis-pharma-teams-up-focusscript-in-specialized-pharmacy-compounds-shares-up-20?source=tweet\" data-url=\"https://seekingalpha.com/news/3232060-imprimis-pharma-teams-up-focusscript-in-specialized-pharmacy-compounds-shares-up-20\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232054\" data-ts=\"1482350646\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DYSL\" target=\"_blank\">DYSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232054-dynasil-corporation-of-america-reports-fy16-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dynasil Corporation of America reports FY16 results</a></h4><ul>\n<li>Dynasil Corporation of America (NASDAQ:<a href=\"https://seekingalpha.com/symbol/DYSL\" title=\"Dynasil Corporation of America\">DYSL</a>): FY16 EPS of $0.04</li>\n<li>Revenue of $43.44M (+7.2% Y/Y)</li>\n<li>Shares <font color=\"green\">+4%</font>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232054\" data-linked=\"Dynasil Corporation of America reports FY16 results\" data-tweet=\"$DYSL - Dynasil Corporation of America reports FY16 results https://seekingalpha.com/news/3232054-dynasil-corporation-of-america-reports-fy16-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3232054-dynasil-corporation-of-america-reports-fy16-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232052\" data-ts=\"1482350405\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232052-technology-top-5-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/INAP' title='Internap Network Services Corporation'>INAP</a> <font color='green'>+42%</font>. <a href='https://seekingalpha.com/symbol/INVN' title='InvenSense'>INVN</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/LIVE' title='Live Ventures'>LIVE</a> <font color='green'>+16%</font>. DRAM <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/TWLO' title='Twilio'>TWLO</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/XGTI' title='xG Technology, Inc.'>XGTI</a> <font color='red'>-56%</font>. <a href='https://seekingalpha.com/symbol/MDSY' title='ModSys International Ltd.'>OTC:MDSY</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/NEON' title='Neonode, Inc.'>NEON</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/KEYW' title='KEYW Holding'>KEYW</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232052\" data-linked=\"Technology - Top 5 Gainers / Losers as of 3:00 pm\" data-tweet=\"$INAP $INVN $LIVE - Technology - Top 5 Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3232052-technology-top-5-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3232052-technology-top-5-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232048\" data-ts=\"1482349706\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CC\" target=\"_blank\">CC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232048-chemoursminus-7-new-jersey-town-files-1_1b-lawsuit-over-waste-dleanup\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chemours -7% as New Jersey town files $1.1B lawsuit over waste dleanup</a></h4><ul>     <li>DuPont spinoff Chemours (<a href=\"https://seekingalpha.com/symbol/CC\" title=\"The Chemours Company\">CC</a> <font color=\"red\">-7.1%</font>) sinks following a report that a New Jersey town filed a lawsuit alleging the company <a href=\"http://www.nj.com/salem/index.ssf/2016/12/small_nj_town_files_11_billion_lawsuit_against_dup.html\" target=\"_blank\">avoided paying $1B-plus in costs</a> to clean up its hazardous waste.</li>     <li>The lawsuit alleges that DuPont's (DD <font color=\"green\">+0.4%</font>) Chambers Works chemical manufacturing plant released more than 100M pounds of toxic chemicals into the town's soil and groundwater, affecting residential areas as far as two miles away, according to the  suit filed on behalf of Carneys Point in Superior Court last week.</li>\n<li>Chambers Works was among a group of properties transferred to Chemours in 2014 and 2015 ahead of a proposed merger with Dow  Chemical, which was carried out to make  DuPont a \"more attractive merger partner,\" according to the lawsuit.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232048\" data-linked=\"Chemours -7% as New Jersey town files $1.1B lawsuit over waste dleanup\" data-tweet=\"$CC $CC $DD - Chemours -7% as New Jersey town files $1.1B lawsuit over waste dleanup https://seekingalpha.com/news/3232048-chemoursminus-7-new-jersey-town-files-1_1b-lawsuit-over-waste-dleanup?source=tweet\" data-url=\"https://seekingalpha.com/news/3232048-chemoursminus-7-new-jersey-town-files-1_1b-lawsuit-over-waste-dleanup\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232047\" data-ts=\"1482348989\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPB\" target=\"_blank\">TPB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232047-turning-point-brands-breaks-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Turning Point Brands breaks higher</a></h4><ul> <li>Shares of Turning Point Brands (<a href=\"https://seekingalpha.com/symbol/TPB\" title=\"Turning Point Brands\">TPB</a> <font color=\"green\">+8.4%</font>) turns higher after some soft trading earlier this week.</li> <li>A <a href=\"http://www.insidermonkey.com/insider-trading/company/turning+point+brands+inc/1290677/purchases/\" target=\"_blank\">minor amount</a> of insider buying was disclosed by Turning Point Brands yesterday.</li> <li>Turning Point specializes in smokeless products and NewGen products - two categories which some analysts see as falling in favor.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3232047\" data-linked=\"Turning Point Brands breaks higher\" data-tweet=\"$TPB - Turning Point Brands breaks higher https://seekingalpha.com/news/3232047-turning-point-brands-breaks-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3232047-turning-point-brands-breaks-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232043\" data-ts=\"1482346940\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NOK\" target=\"_blank\">NOK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232043-nokiaminus-2_45-on-filing-patent-suit-against-apple\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nokia -2.45% on filing patent suit against Apple</a></h4><ul>\n<li>Nokia shares had been trading steadily positive earlier in the session, though are at present reversing sharply intraday amid disclosure <a href=\"https://seekingalpha.com/news/3232035-nokia-sues-apple-europe-u-s-patent-infringement\" target=\"_blank\">the company's filing suits</a> in the U.S. and Europe alleging Apple patent infringement (<a href=\"https://seekingalpha.com/news/3232029-nokia-halted-news\" target=\"_blank\">associated trading halt</a>).</li>\n<li>\n<strong>Current Nokia (NYSE:<a href=\"https://seekingalpha.com/symbol/NOK\" title=\"Nokia Corporation\">NOK</a>) share volume</strong> \u2013 18.105M over 12.661M average</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232043\" data-linked=\"Nokia -2.45% on filing patent suit against Apple\" data-tweet=\"$NOK - Nokia -2.45% on filing patent suit against Apple https://seekingalpha.com/news/3232043-nokiaminus-2_45-on-filing-patent-suit-against-apple?source=tweet\" data-url=\"https://seekingalpha.com/news/3232043-nokiaminus-2_45-on-filing-patent-suit-against-apple\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232034\" data-ts=\"1482344088\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNC\" target=\"_blank\">CNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232034-todays-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Today&#39;s analyst action</a></h4><ul>\n<li>JPMorgan initiates coverage on Centene (<a href=\"https://seekingalpha.com/symbol/CNC\" title=\"Centene Corporation\">CNC</a> <font color=\"green\">+3.3%</font>) with an Overweight rating and $75 (28% upside) price target.</li>\n<li>C.L. King initiates coverage on OraSure Technologies (<a href=\"https://seekingalpha.com/symbol/OSUR\" title=\"OraSure Technologies, Inc.\">OSUR</a> <font color=\"green\">+1.8%</font>) with a Buy rating and $11 (22% upside) price target.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232034\" data-linked=\"Today&#39;s analyst action\" data-tweet=\"$CNC $CNC $OSUR - Today&#39;s analyst action https://seekingalpha.com/news/3232034-todays-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3232034-todays-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232115\" data-ts=\"1482343575\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNCAF\" target=\"_blank\">SNCAF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232115-snc-lavalin-upgraded-to-buy-canaccord-catalyst-rich-story\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SNC-Lavalin upgraded to Buy at Canaccord as &quot;catalyst-rich&quot; story</a></h4><ul>     <li>SNC-Lavalin (<a href=\"https://seekingalpha.com/symbol/SNCAF\" title=\"SNC Lavalin Group Inc.A\">OTCPK:SNCAF</a> <font color=\"green\">+2.9%</font>) is <a href=\"http://business.financialpost.com/investing/trading-desk/snc-lavalin-group-inc-upgraded-as-catalyst-rich-story-for-2017\" target=\"_blank\">upgraded to Buy</a> from Hold with a C$67 price target, raised from C$53, at Canaccord Genuity, as the stock has failed to keep up with the rally in other engineering and construction names since the U.S. election.</li>\n<li>\u201cSure, the company has no meaningful U.S. infrastructure exposure, but it is a dominant player in Canada where the funding outlook is much more clear,\u201d analyst Yuri Lynk writes.</li>\n<li>SNC could be a \u201ccatalyst-rich story for 2017,\u201d Lynk says, as it is shortlisted on $15B worth of new transit projects due to be awarded in 2017, has a new nuclear build opportunity in Argentina, and should benefit from an improving outlook for the mining sector.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232115\" data-linked=\"SNC-Lavalin upgraded to Buy at Canaccord as &quot;catalyst-rich&quot; story\" data-tweet=\"$SNCAF - SNC-Lavalin upgraded to Buy at Canaccord as &quot;catalyst-rich&quot; story https://seekingalpha.com/news/3232115-snc-lavalin-upgraded-to-buy-canaccord-catalyst-rich-story?source=tweet\" data-url=\"https://seekingalpha.com/news/3232115-snc-lavalin-upgraded-to-buy-canaccord-catalyst-rich-story\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232031\" data-ts=\"1482343221\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232031-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FAC' title='First Acceptance Corporation'>FAC</a> <font color='green'>+9%</font>. WAC <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a> <font color='green'>+7%</font>. NCT <font color='green'>+6%</font>.</li><li><b>Losers:</b> WMIH <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/LTS' title='Ladenburg Thalmann Financial Services Inc.'>LTS</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3232031\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$FAC $DHCP $YRD - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3232031-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3232031-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232028\" data-ts=\"1482342418\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232028-cantor-fitzgerald-regards-twitter-shares-range-bound\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cantor Fitzgerald regards Twitter shares range-bound</a></h4><ul>\n<li>Without a takeover or the potential for one, <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/12/8830701/twitter-is-going-through-a-brain-drain\" target=\"_blank\">analyst Youssef Squali</a> stays sidelined on Twitter (<a href=\"https://seekingalpha.com/symbol/TWTR\" title=\"Twitter, Inc.\">TWTR</a> <font color=\"red\">-4.5%</font>) with a $20 fair value target (current price $17.10), suggesting trade in tight range for the near term.</li>\n<li>Further, on <a href=\"https://seekingalpha.com/news/3231835-twitters-cto-departing\" target=\"_blank\">recent management changes</a>: \"These changes obscure the timing and the magnitude of the turnaround required to support a higher valuation for the stock, in our view.\"</li>\n<li>While pointing out positive indicators stemming from recent improvements in user base metrics, potential for a true and sustainable reversal is considered to remain indeterminable.</li>\n<li>Earlier: <a href=\"https://seekingalpha.com/news/3231940-suntrust-robinson-humphrey-views-twitter-management-turnover-materialized-risk\" target=\"_blank\">SunTrust Robinson Humphrey views Twitter management turnover materialized risk</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232028\" data-linked=\"Cantor Fitzgerald regards Twitter shares range-bound\" data-tweet=\"$TWTR - Cantor Fitzgerald regards Twitter shares range-bound https://seekingalpha.com/news/3232028-cantor-fitzgerald-regards-twitter-shares-range-bound?source=tweet\" data-url=\"https://seekingalpha.com/news/3232028-cantor-fitzgerald-regards-twitter-shares-range-bound\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232025\" data-ts=\"1482341965\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232025-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/MRUS\" title=\"Merus\">MRUS</a> <font color=\"green\">+44%</font>. <a href=\"https://seekingalpha.com/symbol/INAP\" title=\"Internap Network Services Corporation\">INAP</a> <font color=\"green\">+36%</font>. <a href=\"https://seekingalpha.com/symbol/MNTX\" title=\"Manitex International, Inc.\">MNTX</a> <font color=\"green\">+24%</font>. <a href=\"https://seekingalpha.com/symbol/PHMD\" title=\"PhotoMedex, Inc.\">PHMD</a> <font color=\"green\">+26%</font>. <a href=\"https://seekingalpha.com/symbol/CALA\" title=\"Calithera Biosciences\">CALA</a> <font color=\"green\">+22%</font>. <a href=\"https://seekingalpha.com/symbol/INVN\" title=\"InvenSense\">INVN</a> <font color=\"green\">+18%</font>. <a href=\"https://seekingalpha.com/symbol/INUV\" title=\"Inuvo, Inc\">INUV</a> <font color=\"green\">+15%</font>. <a href=\"https://seekingalpha.com/symbol/SSY\" title=\"SunLink Health Systems, Inc\">SSY</a> <font color=\"green\">+14%</font>. <a href=\"https://seekingalpha.com/symbol/GRAM-OLD\" title=\"Graña y Montero\">GRAM-OLD</a> <font color=\"green\">+14%</font>. <a href=\"https://seekingalpha.com/symbol/ESEA\" title=\"Euroseas Ltd.\">ESEA</a> <font color=\"green\">+14%</font>.</li>\n<li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/XGTI\" title=\"xG Technology, Inc.\">XGTI</a> <font color=\"red\">-56%</font>. <a href=\"https://seekingalpha.com/symbol/MDSY\" title=\"ModSys International Ltd.\">OTC:MDSY</a> <font color=\"red\">-18%</font>. <a href=\"https://seekingalpha.com/symbol/VNR\" title=\"Vanguard Natural Resources, LLC\">VNR</a> <font color=\"red\">-17%</font>. <a href=\"https://seekingalpha.com/symbol/MACK\" title=\"Merrimack Pharmaceuticals\">MACK</a> <font color=\"red\">-16%</font>. <a href=\"https://seekingalpha.com/symbol/CTRV\" title=\"ContraVir Pharmaceuticals, Inc.\">CTRV</a> <font color=\"red\">-14%</font>. <a href=\"https://seekingalpha.com/symbol/FINL\" title=\"The Finish Line, Inc.\">FINL</a> <font color=\"red\">-11%</font>. <a href=\"https://seekingalpha.com/symbol/RDHL\" title=\"RedHill Biopharma Ltd.\">RDHL</a> <font color=\"red\">-11%</font>. <a href=\"https://seekingalpha.com/symbol/APTO\" title=\"Aptose Biosciences Inc.\">APTO</a> <font color=\"red\">-11%</font>. <a href=\"https://seekingalpha.com/symbol/CPRX\" title=\"Catalyst Pharmaceuticals, Inc.\">CPRX</a> <font color=\"red\">-10%</font>. <a href=\"https://seekingalpha.com/symbol/BCEI\" title=\"Bonanza Creek Energy\">BCEI</a> <font color=\"red\">-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232025\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$MRUS $INAP $MNTX - Midday Gainers / Losers https://seekingalpha.com/news/3232025-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3232025-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232024\" data-ts=\"1482341576\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAK\" target=\"_blank\">BAK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232024-braskem-to-pay-957m-to-settle-foreign-bribery-charges-sec-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Braskem to pay $957M to settle foreign bribery charges, SEC says</a></h4><ul>     <li>Braskem (<a href=\"https://seekingalpha.com/symbol/BAK\" title=\"Braskem S.A.\">BAK</a> <font color=\"green\">+2.4%</font>) <a href=\"http://www.marketwatch.com/story/sec-fines-brazilian-based-petrochemical-company-957-million-for-foreign-bribery-2016-12-21\" target=\"_blank\">agrees to pay $957M to settle charges</a> that it allegedly hid  millions of dollars in illegal bribes paid to Brazilian government  officials by falsifying its financial statements, violating the Foreign Corrupt Practices Act, the SEC <a href=\"https://www.sec.gov/news/pressrelease/2016-271.html\" target=\"_blank\">announces</a>.</li>     <li>The payment is part of a global settlement with the SEC, the U.S. Justice Department and authorities in Brazil and Switzerland.</li>     <li>BAK and Brazilian construction firm Odebrecht pleaded guilty in U.S. federal court, the first guilty pleas in the U.S. following the Operation Car Wash investigation in Brazil into  corruption at Petrobras (<a href=\"https://seekingalpha.com/symbol/PBR\" title=\"Petrobras - Petroleo Brasileiro S.A.\">PBR</a> <font color=\"red\">-0.2%</font>).</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232024\" data-linked=\"Braskem to pay $957M to settle foreign bribery charges, SEC says\" data-tweet=\"$BAK $BAK $PBR - Braskem to pay $957M to settle foreign bribery charges, SEC says https://seekingalpha.com/news/3232024-braskem-to-pay-957m-to-settle-foreign-bribery-charges-sec-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3232024-braskem-to-pay-957m-to-settle-foreign-bribery-charges-sec-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232021\" data-ts=\"1482340890\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ISR\" target=\"_blank\">ISR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232021-isoray-launches-pilot-study-of-cesiumminus-131-in-head-and-neck-cancer-shares-ahead-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IsoRay launches pilot study of Cesium-131 in head and neck cancer; shares ahead 8%</a></h4><ul>\n<li>Thinly traded nano cap IsoRay (<a href=\"https://seekingalpha.com/symbol/ISR\" title=\"IsoRay, Inc.\">ISR</a> <font color=\"green\">+7.9%</font>) shows some life on triple normal volume in response to its announcement that it has initiated a pilot study to assess the effectiveness of Cesium-131 in the management of recurrent head and neck cancer. The study will be conducted at Case Western Reserve University's Case Comprehensive Cancer Center in Cleveland, OH.</li>\n<li>Enrollment of 42 subjects should commence in early Q1. After the enrollment target is met, the study is expected to last 24 months.</li>\n<li>The company's approach to using Cesium-131, a radioisotope, is called <a href=\"https://isoray.com/why-brachytherapy/\" target=\"_blank\">brachytherapy</a>, which involves the surgical placement of radioactive \"seeds\" (about the size of rice grains) directly into the tumor where the radiation dose is release over a period of days.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232021\" data-linked=\"IsoRay launches pilot study of Cesium-131 in head and neck cancer; shares ahead 8%\" data-tweet=\"$ISR - IsoRay launches pilot study of Cesium-131 in head and neck cancer; shares ahead 8% https://seekingalpha.com/news/3232021-isoray-launches-pilot-study-of-cesiumminus-131-in-head-and-neck-cancer-shares-ahead-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3232021-isoray-launches-pilot-study-of-cesiumminus-131-in-head-and-neck-cancer-shares-ahead-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:21 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232020\" data-ts=\"1482340161\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMLS\" target=\"_blank\">CMLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232020-cumulus-media-hands-two-execs-one-time-special-bonuses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cumulus Media hands two execs one-time special bonuses</a></h4><ul>   <li>In a <a href=\"https://seekingalpha.com/filing/3331443\" target=\"_blank\">filing</a>, Cumulus Media (<a href=\"https://seekingalpha.com/symbol/CMLS\" title=\"Cumulus Media Inc.\">CMLS</a> <font color=\"red\">-2%</font>) discloses it's paying a couple of execs some one-time bonuses.</li>    <li>The board approved one-time discretionary bonuses for John Abbot, the executive VP, treasurer and chief financial officer, in the amount of $421,875; and for Richard Denning, senior VP, secretary and general counsel, for $165,000.</li>    <li>Those awards are for \"exceptional efforts and contributions made by those executive officers during 2016, both individually and as members of the management leadership team, in the initial phase of the Company's operational turnaround plan and ongoing operational and financial restructuring.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3232020\" data-linked=\"Cumulus Media hands two execs one-time special bonuses\" data-tweet=\"$CMLS - Cumulus Media hands two execs one-time special bonuses https://seekingalpha.com/news/3232020-cumulus-media-hands-two-execs-one-time-special-bonuses?source=tweet\" data-url=\"https://seekingalpha.com/news/3232020-cumulus-media-hands-two-execs-one-time-special-bonuses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232005\" data-ts=\"1482340016\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLPG\" target=\"_blank\">GLPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232005-galapagoss-cf-candidate-glpg1837-shows-positive-effect-in-mid-stage-study-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galapagos&#39;s CF candidate GLPG1837 shows positive effect in mid-stage study; shares up 3%</a></h4><ul>\n<li>Galapagos NV (<a href=\"https://seekingalpha.com/symbol/GLPG\" title=\"Galapagos\">GLPG</a> <font color=\"green\">+2.7%</font>) perks up on average volume in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1421876/000117184316013727/exh_991.htm\" target=\"_blank\">announcement </a>of positive results from a Phase 2 clinical trial, SAPHIRA 1, assessing CFTR potentiator GLPG1837 for the treatment of cystic fibrosis (CF).</li>\n<li>SAPHIRA 1 involved 26 CF patients with the G551D mutation. 25 were on stable Kalydeco (ivacaftor) therapy at screening and agreed to a one-week washout period before all received three sequential doses of GLPG1837 (125 mg twice daily for seven days followed by 250 mg twice daily for seven days followed by 500 mg twice daily for 14 days).</li>\n<li>A statistically significant dose-dependent decrease in sweat chloride concentration was observed. At the 500 mg dose, the average sweat chloride decreased almost 33% (p&lt;0.0001).</li>\n<li>In the Kalydeco patients, a lung function test called mean percent predicted FEV1 fell 5.4% during the washout period but recovered after treatment with GLPG1837.</li>\n<li>Galapagos and development partner AbbVie (<a href=\"https://seekingalpha.com/symbol/ABBV\" title=\"AbbVie Inc.\">ABBV</a> <font color=\"red\">-0.8%</font>) will further analyze the data before deciding which CFTR potentiator to use in a triple combination therapy.</li>\n<li>Competitor Vertex Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/VRTX\" title=\"Vertex Pharmaceuticals Incorporated\">VRTX</a> <font color=\"red\">-3.5%</font>) eases on average volume.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232005\" data-linked=\"Galapagos&#39;s CF candidate GLPG1837 shows positive effect in mid-stage study; shares up 3%\" data-tweet=\"$GLPG $GLPG $ABBV - Galapagos&#39;s CF candidate GLPG1837 shows positive effect in mid-stage study; shares up 3% https://seekingalpha.com/news/3232005-galapagoss-cf-candidate-glpg1837-shows-positive-effect-in-mid-stage-study-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3232005-galapagoss-cf-candidate-glpg1837-shows-positive-effect-in-mid-stage-study-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232014\" data-ts=\"1482339419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNTX\" target=\"_blank\">MNTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232014-manitexplus-23-on-improved-outlook-for-2017\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Manitex +23 on improved outlook for 2017</a></h4><ul>\n<li>Manitex International (<a href=\"https://seekingalpha.com/symbol/MNTX\" title=\"Manitex International, Inc.\">MNTX</a> <font color=\"green\">+23%</font>) shares jump after the provider of engineered specialty lifting and loading products issues an update on trends in its business activity in H2 2016 that suggest an improved outlook for 2017.</li>\n<li>MNTX says its backlog for straight mast cranes in Q4 has doubled  since Q3, and management anticipates ending Q4 with a book to bill ratio  for straight mast cranes exceeding 1.0.</li>\n<li>MNTX says it is \"encouraged to see growth in orders from dealers who are replenishing  decreased inventory levels as they respond to improving market activity.\"</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232014\" data-linked=\"Manitex +23 on improved outlook for 2017\" data-tweet=\"$MNTX - Manitex +23 on improved outlook for 2017 https://seekingalpha.com/news/3232014-manitexplus-23-on-improved-outlook-for-2017?source=tweet\" data-url=\"https://seekingalpha.com/news/3232014-manitexplus-23-on-improved-outlook-for-2017\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232011\" data-ts=\"1482338976\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SUN\" target=\"_blank\">SUN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232011-sunoco-upgraded-credit-suisse-which-says-distribution-cut-unlikely\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sunoco upgraded at Credit Suisse, which says distribution cut unlikely</a></h4><ul>     <li>Sunoco LP (<a href=\"https://seekingalpha.com/symbol/SUN\" title=\"Sunoco LP\">SUN</a> <font color=\"green\">+6.3%</font>) surges after Credit Suisse <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/12/8830243/sunoco-shares-a-buy-on-credit-suisses-upgrade-to-outperf\" target=\"_blank\">upgrades</a> shares to Outperform from Neutral with a $31 price target, saying a distribution cut is unlikely given options available for Sunoco and Energy Transfer to execute before reducing payouts.</li>     <li>Taking into account the pending dilutive merger of Sunoco Logistics Partners (<a href=\"https://seekingalpha.com/symbol/SXL\" title=\"Sunoco Logistics Partners, L.P.\">SXL</a> <font color=\"green\">+0.5%</font>) and Energy Transfer Partners (ETP <font color=\"green\">+0.7%</font>), CS analyst John Edwards says a distribution cut seems to be a \u201clogically unviable option,\u201d even though it would mean \u201cimmediate and significant\u201d cash savings of $230M/year.</li>     <li>Edwards says an issuance of convertible preferred units to Energy Transfer Equity (ETE <font color=\"green\">+1.3%</font>), a two-year incentive distribution rights waiver and deferring distribution growth by a year seems \u201cthe most likely path to be adopted by SUN to rescue its balance sheet and continue on its expected growth trajectory.\u201d</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232011\" data-linked=\"Sunoco upgraded at Credit Suisse, which says distribution cut unlikely\" data-tweet=\"$SUN $SUN $SXL - Sunoco upgraded at Credit Suisse, which says distribution cut unlikely https://seekingalpha.com/news/3232011-sunoco-upgraded-credit-suisse-which-says-distribution-cut-unlikely?source=tweet\" data-url=\"https://seekingalpha.com/news/3232011-sunoco-upgraded-credit-suisse-which-says-distribution-cut-unlikely\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>64&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232010\" data-ts=\"1482338970\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JNJ\" target=\"_blank\">JNJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232010-johnson-johnson-back-table-actelion\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Johnson &amp; Johnson back at the table with Actelion</a></h4><ul><li>Johnson &amp; Johnson (<a href=\"https://seekingalpha.com/symbol/JNJ\" title=\"Johnson &amp; Johnson\">JNJ</a> <font color=\"red\">-0.3%</font>) reports that it is negotiating with Actelion (<a href=\"https://seekingalpha.com/symbol/ALIOY\" title=\"Actelion Ltd. ADR\">OTCPK:ALIOY</a>) about a possible transaction, an about-face from its earlier withdrawal after Actelion's apparent rejection of its $250/share bid. Sanofi (<a href=\"https://seekingalpha.com/symbol/SNY\" title=\"Sanofi\">SNY</a> <font color=\"green\">+2.2%</font>) is also in the running for the Swiss biopharma firm at ~$275/share.</li></ul><div class=\"tiny-share-widget\" data-id=\"3232010\" data-linked=\"Johnson &amp; Johnson back at the table with Actelion\" data-tweet=\"$JNJ $JNJ $ALIOY - Johnson &amp; Johnson back at the table with Actelion https://seekingalpha.com/news/3232010-johnson-johnson-back-table-actelion?source=tweet\" data-url=\"https://seekingalpha.com/news/3232010-johnson-johnson-back-table-actelion\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232002\" data-ts=\"1482337732\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNCE\" target=\"_blank\">CNCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232002-concert-pharma-launches-mid-stage-study-of-cf-candidate-ctpminus-656-competitor-vertex-off-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Concert Pharma launches mid-stage study of CF candidate CTP-656; competitor Vertex off 3%</a></h4><ul>\n<li>Concert Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/CNCE\" title=\"Concert Pharmaceuticals, Inc.\">CNCE</a> <font color=\"red\">-0.4%</font>) initiates a Phase 2 clinical trial assessing next-generation CFTR potentiator CTP-656 for the treatment of cystic fibrosis (CF). Top-line data are expected by the end of 2017.</li>\n<li>CTP-656 is a deuterium-modified version of ivacaftor [Vertex Pharmaceuticals' (<a href=\"https://seekingalpha.com/symbol/VRTX\" title=\"Vertex Pharmaceuticals Incorporated\">VRTX</a> <font color=\"red\">-3.4%</font>) Kalydeco]. The company says its version has a superior pharmacokinetic profile.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3232002\" data-linked=\"Concert Pharma launches mid-stage study of CF candidate CTP-656; competitor Vertex off 3%\" data-tweet=\"$CNCE $CNCE $VRTX - Concert Pharma launches mid-stage study of CF candidate CTP-656; competitor Vertex off 3% https://seekingalpha.com/news/3232002-concert-pharma-launches-mid-stage-study-of-cf-candidate-ctpminus-656-competitor-vertex-off-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3232002-concert-pharma-launches-mid-stage-study-of-cf-candidate-ctpminus-656-competitor-vertex-off-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3232001\" data-ts=\"1482337494\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AF\" target=\"_blank\">AF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3232001-astoria-financialplus-3-gains-continue-after-merger-break-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Astoria Financial +3% as gains continue after merger break-up</a></h4><ul><li>What's \"stronger together\" is \"weaker apart,\" says FBR's Bob Ramsey, who fades the action in Astoria Financial (<a href='https://seekingalpha.com/symbol/AF' title='Astoria Financial Corporation'>AF</a> <font color='green'>+3.1%</font>) with a downgrade to Underperform from Market Perform (he <a href=\"https://seekingalpha.com/news/3231937-nycb-minus-2_4-percent-sell-side-bails\" target=\"_blank\">also downgraded</a> NYCB).</li><li>He thinks a better offer is unlikely, and the current valuation (now&nbsp;<font color='green'>up nearly 6%&nbsp;</font>since its sale fell apart) reflects takeout hopes, rather than fundamentals.</li><li>Other serious bidders like Investors Bancorp (<a href='https://seekingalpha.com/symbol/ISBC' title='Investors Bancorp, Inc.'>ISBC</a>) and People's United (<a href='https://seekingalpha.com/symbol/PBCT' title='People&#39;s United Financial, Inc.'>PBCT</a> <font color='red'>-0.1%</font>) are now otherwise occupied, notes Ramsey, and activist Basswood Capital today <a href=\"https://seekingalpha.com/filing/3331447\" target=\"_blank\">disclosed a</a> reduced stake in Astoria.</li><li>Look for Astoria early next year to announce a strategic update with cost cuts, and plans to begin putting money to work.</li></ul><div class=\"tiny-share-widget\" data-id=\"3232001\" data-linked=\"Astoria Financial +3% as gains continue after merger break-up\" data-tweet=\"$AF $AF $ISBC - Astoria Financial +3% as gains continue after merger break-up https://seekingalpha.com/news/3232001-astoria-financialplus-3-gains-continue-after-merger-break-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3232001-astoria-financialplus-3-gains-continue-after-merger-break-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231999\" data-ts=\"1482337325\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWLO\" target=\"_blank\">TWLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231999-twilioplus-4_9-unconfirmed-reports-of-expanded-amazon-partnership-circulating\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twilio +4.9%, unconfirmed reports of expanded Amazon partnership circulating</a></h4><ul><li><a href=\"http://www.benzinga.com/news/16/12/8831231/source-familiar-with-matter-tells-benzinga-amazon-will-further-expand-relationshi\" target=\"_blank\">Benzinga notes</a> sources familiar with the matter suggest expansion of an existing relationship between Twilio (NYSE:<a href='https://seekingalpha.com/symbol/TWLO' title='Twilio'>TWLO</a>)&nbsp;and Amazon involving voice solutions targeting management and scaling of communications.</li><li>Details limited.</li></ul><div class=\"tiny-share-widget\" data-id=\"3231999\" data-linked=\"Twilio +4.9%, unconfirmed reports of expanded Amazon partnership circulating\" data-tweet=\"$TWLO - Twilio +4.9%, unconfirmed reports of expanded Amazon partnership circulating https://seekingalpha.com/news/3231999-twilioplus-4_9-unconfirmed-reports-of-expanded-amazon-partnership-circulating?source=tweet\" data-url=\"https://seekingalpha.com/news/3231999-twilioplus-4_9-unconfirmed-reports-of-expanded-amazon-partnership-circulating\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231998\" data-ts=\"1482337078\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TKPHF\" target=\"_blank\">TKPHF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231998-tigenix-up-4-on-10m-takeda-investment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TiGenix up 4% on \u20ac10M Takeda investment</a></h4><ul>\n<li>Takeda Pharmaceutical (<a href=\"https://seekingalpha.com/symbol/TKPHF\" title=\"Takeda Pharmaceutical Co., Ltd.\">OTCPK:TKPHF</a>)(TKPYY) exercises its option to invest \u20ac10M in Belgian biotech TiGenix NV (<a href=\"https://seekingalpha.com/symbol/TIG\" title=\"TiGenix NV  (ADS)\">TIG</a> <font color=\"green\">+4%</font>) by purchasing 11,651,778 newly issued ordinary shares at \u20ac0.858. The new shares, subject to a one-year lockup, should be issued in the first week of January.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3191648-takeda-nabs-ex-u-s-rights-investigational-stem-cell-treatment-crohns-related-fistulas\" target=\"_blank\">Takeda nabs ex-U.S. rights to investigational stem cell treatment for Crohn's-related fistulas</a> (July 5)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231998\" data-linked=\"TiGenix up 4% on \u20ac10M Takeda investment\" data-tweet=\"$TKPHF $TKPHF $TAK - TiGenix up 4% on \u20ac10M Takeda investment https://seekingalpha.com/news/3231998-tigenix-up-4-on-10m-takeda-investment?source=tweet\" data-url=\"https://seekingalpha.com/news/3231998-tigenix-up-4-on-10m-takeda-investment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231995\" data-ts=\"1482336495\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FEYE\" target=\"_blank\">FEYE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231995-fireeyeminus-3_85-piper-jaffray-observes-declining-demand-among-resellers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FireEye -3.85%, Piper Jaffray observes declining demand among resellers</a></h4><ul>\n<li>\n<a href=\"http://blogs.barrons.com/techtraderdaily/2016/12/21/palo-alto-gets-great-marks-fireeye-deteriorates-in-piper-survey/\" target=\"_blank\">Analyst Andrew Nowinski</a>, subsequent meetings with investors, security technology consultants and resellers, suggests FIreEye (NASDAQ:<a href=\"https://seekingalpha.com/symbol/FEYE\" title=\"FireEye, Inc.\">FEYE</a>) products are no longer leading in advanced threat protection at those resellers observed. Further: \"Most believe advanced threat protection is just a feature on a larger platform, though we would argue that FireEye has assembled a larger platform of integrated products. The company now has virtual/subscription-based versions of their products, including their flagship NX-series. We believe the new head of sales Bill Robbins has a lot of work ahead of him re-engaging key channel partners.\"</li>\n<li>Further issues contrastingly positive sentiment regarding competitors Palo Alto Networks (<a href=\"https://seekingalpha.com/symbol/PANW\" title=\"Palo Alto Networks\">PANW</a> <font color=\"red\">-0.5%</font>), Symantec (<a href=\"https://seekingalpha.com/symbol/SYMC\" title=\"Symantec Corporation\">SYMC</a> <font color=\"red\">-0.1%</font>) and Proofpoint (<a href=\"https://seekingalpha.com/symbol/PFPT\" title=\"Proofpoint, Inc.\">PFPT</a> <font color=\"red\">-2.6%</font>), citing more favorable reseller feedback indicated for each.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231995\" data-linked=\"FireEye -3.85%, Piper Jaffray observes declining demand among resellers\" data-tweet=\"$FEYE $FEYE $PANW - FireEye -3.85%, Piper Jaffray observes declining demand among resellers https://seekingalpha.com/news/3231995-fireeyeminus-3_85-piper-jaffray-observes-declining-demand-among-resellers?source=tweet\" data-url=\"https://seekingalpha.com/news/3231995-fireeyeminus-3_85-piper-jaffray-observes-declining-demand-among-resellers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231989\" data-ts=\"1482336191\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INO\" target=\"_blank\">INO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231989-inovios-zika-vaccine-candidate-elicits-significant-antibody-responses-in-early-stage-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Inovio&#39;s Zika vaccine candidate elicits significant antibody responses in early-stage study; shares ahead 6%</a></h4><ul>\n<li>Inovio Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/INO\" title=\"Inovio Pharmaceuticals, Inc.\">INO</a> <font color=\"green\">+5.9%</font>) perks up on increased volume in response to its announcement of positive results from a Phase 1 trial assessing its DNA-based Zika vaccine GLS-5700. In initial testing, Zika-naive subjects in the low-dose and high-dose groups showed Zika antigen-specific antibody responses after one or two vaccinations. No significant safety signals were observed in any of the 40 healthy volunteers for up to 14 weeks post dosing.</li>\n<li>A second Phase 1 involving 160 subjects in Puerto Rico should be completed shortly. The company intends to meet with regulators to discuss the data from the two studies and clarify a regulatory path leading to a marketing application.</li>\n<li>The company is developing GLS-5700 with GeneOne Life Science and academic collaborators from the U.S. and Canada.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231989\" data-linked=\"Inovio&#39;s Zika vaccine candidate elicits significant antibody responses in early-stage study; shares ahead 6%\" data-tweet=\"$INO - Inovio&#39;s Zika vaccine candidate elicits significant antibody responses in early-stage study; shares ahead 6% https://seekingalpha.com/news/3231989-inovios-zika-vaccine-candidate-elicits-significant-antibody-responses-in-early-stage-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3231989-inovios-zika-vaccine-candidate-elicits-significant-antibody-responses-in-early-stage-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231970\" data-ts=\"1482336003\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231970-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CALA' title='Calithera Biosciences'>CALA</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/MRUS' title='Merus'>MRUS</a> <font color='green'>+47%</font>. <a href='https://seekingalpha.com/symbol/SSY' title='SunLink Health Systems, Inc'>SSY</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/OPGN' title='OpGen'>OPGN</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/PHMD' title='PhotoMedex, Inc.'>PHMD</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MACK' title='Merrimack Pharmaceuticals'>MACK</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/RDHL' title='RedHill Biopharma Ltd.'>RDHL</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/GTXI' title='GTx, Inc.'>GTXI</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3231970\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$CALA $MRUS $SSY - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3231970-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3231970-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231992\" data-ts=\"1482335867\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GST\" target=\"_blank\">GST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231992-gastar-explorationplus-11-on-stack-optimism\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gastar Exploration +11% on STACK optimism</a></h4><ul>\n<li>Gastar Exploration (<a href=\"https://seekingalpha.com/symbol/GST\" title=\"Gastar Exploration Inc.\">GST</a> <font color=\"green\">+10.5%</font>) surges to seven-month highs, capping a 22% burst over the past four trading sessions.</li>\n<li>The market is recognizing the Oklahoma STACK, where GST is a leading producer, as a \u201cpremier play,\u201d CFO Mike Gerlich tells Bloomberg.</li>\n<li>GST may rise on a potential sale of closely held STACK driller Staghorn Petroleum, according to Canaccord Genuity analyst Stephen Berman.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231992\" data-linked=\"Gastar Exploration +11% on STACK optimism\" data-tweet=\"$GST - Gastar Exploration +11% on STACK optimism https://seekingalpha.com/news/3231992-gastar-explorationplus-11-on-stack-optimism?source=tweet\" data-url=\"https://seekingalpha.com/news/3231992-gastar-explorationplus-11-on-stack-optimism\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231986\" data-ts=\"1482335308\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INAP\" target=\"_blank\">INAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231986-internapplus-28-next-restructuring-steps-promised\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Internap +28% as next restructuring steps promised</a></h4><ul>\n<li>Internap (<a href=\"https://seekingalpha.com/symbol/INAP\" title=\"Internap Network Services Corporation\">INAP</a> <font color=\"green\">+28.3%</font>) announces the completion of its initial round of cost cuts and guides for next year. Part of the plan calls for raising new money, whether through equity sales or borrowing.</li>\n<li>The company is also evaluating the sale of non-core assets and expects to discontinue non-profitable programs.</li>\n<li>As a result, full-year 2017 revenue is expected to fall to $275M-$285M, and adjusted EBITDA to rise to $84M-$87M. Capex is expected to decline to $42M. The combination should result in significantly higher free cash flow.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231986\" data-linked=\"Internap +28% as next restructuring steps promised\" data-tweet=\"$INAP - Internap +28% as next restructuring steps promised https://seekingalpha.com/news/3231986-internapplus-28-next-restructuring-steps-promised?source=tweet\" data-url=\"https://seekingalpha.com/news/3231986-internapplus-28-next-restructuring-steps-promised\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231985\" data-ts=\"1482335289\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZRX\" target=\"_blank\">AZRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231985-first-patients-enrolled-in-azurrx-bios-mid-stage-study-of-ms1819-sd-in-epi-shares-ahead-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">First patients enrolled in AzurRx Bio&#39;s mid-stage study of MS1819-SD in EPI; shares ahead 9%</a></h4><ul>\n<li>Thinly traded nano cap <a href=\"http://www.azurrx.com/\" target=\"_blank\">AzurRx BioPharma</a> (<a href=\"https://seekingalpha.com/symbol/AZRX\" title=\"AzurRX Biopharma\">AZRX</a> <font color=\"green\">+8.6%</font>) perks up, albeit on only ~15K shares, in response to its announcement that the first three patients have been enrolled in its Phase 2a clinical trial assessing lead product candidate MS1819-SD for the treatment of patients with exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis (CP).</li>\n<li>The open-label study will enroll as many as 15 EPI patients over the next few months. The primary objective is the safety of escalating doses of MS1819-SD. The secondary objective is the efficacy dose response as determined by the change from baseline in the coefficient of fat absorption.</li>\n<li>Top-line data from the first group of subjects should be available in H1 2017.</li>\n<li>MS1819-SD is an oral non-systemic biologic capsule that contains a recombinant enzyme designed to compensate for the deficiency in pancreatic lipase in CP patients.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231985\" data-linked=\"First patients enrolled in AzurRx Bio&#39;s mid-stage study of MS1819-SD in EPI; shares ahead 9%\" data-tweet=\"$AZRX - First patients enrolled in AzurRx Bio&#39;s mid-stage study of MS1819-SD in EPI; shares ahead 9% https://seekingalpha.com/news/3231985-first-patients-enrolled-in-azurrx-bios-mid-stage-study-of-ms1819-sd-in-epi-shares-ahead-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3231985-first-patients-enrolled-in-azurrx-bios-mid-stage-study-of-ms1819-sd-in-epi-shares-ahead-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231980\" data-ts=\"1482334347\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LBCC\" target=\"_blank\">LBCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231980-long-island-iced-tea-prices-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Long Island Iced Tea prices offering</a></h4><ul> <li>Long Island Iced Tea Corp. (LTEA <font color=\"red\">-13.4%</font>) announces it priced its offering of 399,050 shares at $4.00 per share.</li>\n<li>The offering is expected to close on December 27.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231980\" data-linked=\"Long Island Iced Tea prices offering\" data-tweet=\"$LBCC - Long Island Iced Tea prices offering https://seekingalpha.com/news/3231980-long-island-iced-tea-prices-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3231980-long-island-iced-tea-prices-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231978\" data-ts=\"1482333949\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DKS\" target=\"_blank\">DKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231978-drop-in-dicks-sporting-goods-seen-buying-opportunity\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Drop in Dick&#39;s Sporting Goods seen an buying opportunity</a></h4><ul> <li>Shares of Dick's Sporting Goods (NYSE:<a href=\"https://seekingalpha.com/symbol/DKS\" title=\"Dick's Sporting Goods, Inc.\">DKS</a>) are <font color=\"green\">down 2.57%</font> after reports from Finish Line and Nike give investors a fresh look at industry trends. Some traders think the drop is unjustified based on Dick's sales growth projections.</li> <li>Earlier this month, <a href=\"https://seekingalpha.com/author/forward-view/articles#regular_articles\" target=\"_blank\">Forward View's</a> Nathan Yates noted that investors seemed unimpressed by the solid guidance from Dick's on 2017. \"The company\u2019s business is going to make investors happy in 2017,\" wrote Yates.</li>\n<li>Dick's trade about 10% below its 52-week high</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3231978\" data-linked=\"Drop in Dick&#39;s Sporting Goods seen an buying opportunity\" data-tweet=\"$DKS - Drop in Dick&#39;s Sporting Goods seen an buying opportunity https://seekingalpha.com/news/3231978-drop-in-dicks-sporting-goods-seen-buying-opportunity?source=tweet\" data-url=\"https://seekingalpha.com/news/3231978-drop-in-dicks-sporting-goods-seen-buying-opportunity\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231971\" data-ts=\"1482332672\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VBIO\" target=\"_blank\">VBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231971-regulators-ok-vitality-bios-cannabinoid-pharma-development-facility-shares-up-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Regulators OK Vitality Bio&#39;s cannabinoid pharma development facility; shares up 8%</a></h4><ul>\n<li>The U.S. Drug Enforcement Agency (DEA) and the California Research Advisory Panel have approved the scale-up of <a href=\"http://vitality.bio/\" target=\"_blank\">Vitality Biopharma's</a> (<a href=\"https://seekingalpha.com/symbol/VBIO\" title=\"Vitality Biopharma, Inc.\">OTC:VBIO</a> <font color=\"green\">+7.6%</font>) facilities used to develop cannabinoid pharmaceutical prodrugs. The DEA in particular wanted to make sure that the company instituted on-site measures to prevent the diversion of Schedule I controlled substances.</li>\n<li>Vitality co-founder Dr. Brandon Zipp says, \"We are excited to scale up our research and to aggressively pursue clinical testing of our compounds, and this approval greenlights that work. There are surprisingly few companies in the United States that are properly licensed and developing differentiated cannabinoid pharmaceutical products.\"</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231971\" data-linked=\"Regulators OK Vitality Bio&#39;s cannabinoid pharma development facility; shares up 8%\" data-tweet=\"$VBIO - Regulators OK Vitality Bio&#39;s cannabinoid pharma development facility; shares up 8% https://seekingalpha.com/news/3231971-regulators-ok-vitality-bios-cannabinoid-pharma-development-facility-shares-up-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3231971-regulators-ok-vitality-bios-cannabinoid-pharma-development-facility-shares-up-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231958\" data-ts=\"1482330383\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDHL\" target=\"_blank\">RDHL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231958-redhill-bio-prices-equity-offering-shares-off-12-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RedHill Bio prices equity offering; shares off 12% premarket</a></h4><ul>\n<li>RedHill Biopharma (NASDAQ:<a href=\"https://seekingalpha.com/symbol/RDHL\" title=\"RedHill Biopharma Ltd.\">RDHL</a>) slumps <font color=\"red\">12%</font> premarket on average volume in response to the pricing of its public offering of 2.25M American Depositary Shares (ADSs) and warrants to purchase 1.125M ADSs at a combined price of $10.25. Each ADS represents 10 ordinary shares.</li>\n<li>Concurrently, the company is executing a direct offering of 1,463,415 ADSs and warrants to purchase 731,708 ADSs.</li>\n<li>Each three-year warrant can buy 1/2 of an ADS at $13.33.</li>\n<li>Underwriters over-allotment is an additional 337,500 ADSs and warrants to purchase up to 168,750 ADSs.</li>\n<li>Net proceeds will fund clinical development activities, potential acquisitions, commercial operations and general corporate purposes. Closing date is December 27.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231958\" data-linked=\"RedHill Bio prices equity offering; shares off 12% premarket\" data-tweet=\"$RDHL - RedHill Bio prices equity offering; shares off 12% premarket https://seekingalpha.com/news/3231958-redhill-bio-prices-equity-offering-shares-off-12-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3231958-redhill-bio-prices-equity-offering-shares-off-12-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231957\" data-ts=\"1482330314\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231957-long-term-tnt-benefits-still-story-fedex\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Long-term TNT benefits still the story at FedEx</a></h4><ul> <li>FedEx (NYSE:<a href=\"https://seekingalpha.com/symbol/FDX\" title=\"FedEx Corporation\">FDX</a>) is lower in premarket trading after the company disclosed higher costs associated with the TNT business.</li> <li>During the earnings call (<a href=\"https://seekingalpha.com/article/4031831-fedexs-fdx-ceo-fred-smith-q2-2017-results-earnings-call-transcript\" target=\"_blank\">transcript</a>), FedEx execs put a number to the TNT integration ($700M-$800M over four years), while reiterating that after 2020 the shipper will see pre-tax synergies of $750M per year.</li> <li>The short-term pressure on ground margins is also seen falling off over time as new tech and logistics investments kick in.</li> <li>On Wall Street, Baird says buy the dip on FDX and Cowen advises investors to stay locked in on the long term. The consensus view is to skip over the year-over-year margin comparisons due to the changing FDX model.</li> <li>FDX <font color=\"red\">-1.88%</font> premarket to $195.00 vs. a 52-week range of $119.71 to $201.57.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231957\" data-linked=\"Long-term TNT benefits still the story at FedEx\" data-tweet=\"$FDX - Long-term TNT benefits still the story at FedEx https://seekingalpha.com/news/3231957-long-term-tnt-benefits-still-story-fedex?source=tweet\" data-url=\"https://seekingalpha.com/news/3231957-long-term-tnt-benefits-still-story-fedex\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231954\" data-ts=\"1482330047\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENDP\" target=\"_blank\">ENDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231954-endo-announces-organizational-restructuring-shares-off-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endo announces organizational restructuring; shares off 1% premarket</a></h4><ul> <li>Endo International (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ENDP\" title=\"Endo International plc\">ENDP</a>) announces that it has appointed Patrick Barry as Senior Vice President, U.S. Branded Pharmaceuticals, effective immediately, and Matthew Davis, M.D., R.Ph., as Senior Vice President, R&amp;D Branded Pharmaceuticals, effective January 3, 2017.</li>    <li>Prior to joining Endo, Mr. Barry worked at Sanofi for over two decades and Dr. Davis served as the Chief Medical Officer of Lupin Pharmaceuticals before joining the company.</li>  <li>Joseph Ciaffoni, President U.S. Branded Pharmaceuticals and Dr. Susan Hall, Executive Vice President, Chief Scientific Officer and Global Head of R&amp;D will leave the Company as a part of the restructuring.</li>\n<li>Shares are down <font color=\"red\">1%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3231954\" data-linked=\"Endo announces organizational restructuring; shares off 1% premarket\" data-tweet=\"$ENDP - Endo announces organizational restructuring; shares off 1% premarket https://seekingalpha.com/news/3231954-endo-announces-organizational-restructuring-shares-off-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3231954-endo-announces-organizational-restructuring-shares-off-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231953\" data-ts=\"1482329765\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231953-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul> <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MRUS' title='Merus'>MRUS</a> <font color='green'>+55%</font>. <a href='https://seekingalpha.com/symbol/ESEA' title='Euroseas Ltd.'>ESEA</a> <font color='green'>+32%</font>. <a href='https://seekingalpha.com/symbol/CALA' title='Calithera Biosciences'>CALA</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/INVN' title='InvenSense'>INVN</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/OPGN' title='OpGen'>OPGN</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SINO' title='Sino-Global Shipping America, Ltd.'>SINO</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/LXRX' title='Lexicon Pharmaceuticals, Inc.'>LXRX</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/GST' title='Gastar Exploration Inc.'>GST</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='green'>+5%</font>.</li> <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/XGTI' title='xG Technology, Inc.'>XGTI</a> <font color='red'>-56%</font>. <a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a> <font color='red'>-14%</font>. LTEA <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/RDHL' title='RedHill Biopharma Ltd.'>RDHL</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/MACK' title='Merrimack Pharmaceuticals'>MACK</a> <font color='red'>-9%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3231953\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$MRUS $ESEA $CALA - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3231953-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3231953-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231950\" data-ts=\"1482329202\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEOG\" target=\"_blank\">NEOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231950-neogen-revenues-up-14-earnings-up-23-in-fq2-shares-off-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neogen revenues up 14%; earnings up 23% in FQ2, shares off 4% premarket</a></h4><ul>\n<li>Neogen (<a href=\"https://seekingalpha.com/symbol/NEOG\" title=\"Neogen Corporation\">NEOG</a>) FQ2 results: Revenues: $90.7M (+13.9%); Operating Income: $16.9M (+15.8%); Net Income: $11.2M (+23.1%); EPS: $0.29 (+20.8%); Quick Assets: $142.1M (+31.8%).</li>\n<li>No guidance given.</li>\n<li>Shares are down <font color=\"red\">4%</font> premarket.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231950\" data-linked=\"Neogen revenues up 14%; earnings up 23% in FQ2, shares off 4% premarket\" data-tweet=\"$NEOG - Neogen revenues up 14%; earnings up 23% in FQ2, shares off 4% premarket https://seekingalpha.com/news/3231950-neogen-revenues-up-14-earnings-up-23-in-fq2-shares-off-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3231950-neogen-revenues-up-14-earnings-up-23-in-fq2-shares-off-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231943\" data-ts=\"1482328610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231943-nike-sized-up-after-key-earnings-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike sized up after key earnings report</a></h4><ul> <li>Nike (NYSE:<a href=\"https://seekingalpha.com/symbol/NKE\" title=\"Nike Inc.\">NKE</a>) is <font color=\"green\">up 1.47%</font> in premarket trading after the company beat Q2 estimates. Shares were initially even higher before the Swoosh reported during its conference call that futures orders growth was below analyst expectations.</li> <li>During Nike's call (<a href=\"https://seekingalpha.com/article/4031819-nikes-nke-ceo-mark-parker-q2-2017-results-earnings-call-transcript\" target=\"_blank\">transcript</a>), execs pointed to the 25% increase in direct-to-consumer sales. Upside in China and a resurgence in the basketball business were also cited.</li> <li>Analysts are weighing in full force after the Nike report..</li> <li>B. Riley: Analyst Mitch Kummetz <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8830008/nikes-guidance-remains-aggressive-relative-to-futures-or\" target=\"_blank\">points out</a> that Nike delivered its profit beat through a reduced SG&amp;A spend.</li> <li>Wells Fargo: The firm sticks with a Market Perform rating after taking in the \"choppy\" top-line trends in North America. Gross margin rates are also seen as a concern.</li> <li>Stifel Nicolaus: Analyst Jim Duffy says the weak futures orders mark is part of a structural shift away from the old sales model, including more direct-to-consumer engagement and retailer reticence to advance commitments. Solid execution by Nike keeps Stifel positive (Buy, $68 PT) on the stock.</li>\n<li>\n<a href=\"https://seekingalpha.com/article/4031884-nike-turn-underway\" target=\"_blank\">Stone Fox Capital</a>: \"The growth trajectory remains a question for anybody buying what really isn't that beaten up of a stock.\"</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3231813-nike-delivers-earnings-surprise\" target=\"_blank\">Nike delivers earnings surprise</a> (Dec. 20)</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3231867-nike-call-futures-orders-light-momentum-basketball\" target=\"_blank\">Nike call: Futures orders light, momentum in basketball</a> (Dec. 20)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3231943\" data-linked=\"Nike sized up after key earnings report\" data-tweet=\"$NKE - Nike sized up after key earnings report https://seekingalpha.com/news/3231943-nike-sized-up-after-key-earnings-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3231943-nike-sized-up-after-key-earnings-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231940\" data-ts=\"1482328439\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231940-suntrust-robinson-humphrey-views-twitter-management-turnover-materialized-risk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SunTrust Robinson Humphrey views Twitter management turnover materialized risk</a></h4><ul>\n<li>\n<a href=\"http://www.streetinsider.com/Analyst+Comments/SunTrust+Robinson+Humphrey+Remains+Sidelined+on+Twitter+%28TWTR%29+Following+Announced+Departure+of+Adam+Messinger/12362456.html\" target=\"_blank\">Analyst Rodney Hull</a> continues sidelined coverage on Twitter (NYSE:<a href=\"https://seekingalpha.com/symbol/TWTR\" title=\"Twitter, Inc.\">TWTR</a>) amid news the company's <a href=\"https://seekingalpha.com/news/3231835-twitters-cto-departing\" target=\"_blank\">CTO is set to leave</a>, the latest development in a series of <a href=\"https://seekingalpha.com/news/3223119-twitter-initiates-search-new-cfo-coo-departing\" target=\"_blank\">significant executive role adjustments</a> transpiring of late.</li>\n<li>Further: \"Management turnover was a potential risk that has materialized. This level of turnover can be disruptive to morale and product execution and we are concerned this wave of defections could continue.\"</li>\n<li>Retains target on Twitter shares, <font color=\"red\">lower by 1.51%</font> pre-market to $17.65, at $18.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231940\" data-linked=\"SunTrust Robinson Humphrey views Twitter management turnover materialized risk\" data-tweet=\"$TWTR - SunTrust Robinson Humphrey views Twitter management turnover materialized risk https://seekingalpha.com/news/3231940-suntrust-robinson-humphrey-views-twitter-management-turnover-materialized-risk?source=tweet\" data-url=\"https://seekingalpha.com/news/3231940-suntrust-robinson-humphrey-views-twitter-management-turnover-materialized-risk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231937\" data-ts=\"1482327970\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NYCB\" target=\"_blank\">NYCB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231937-nycbminus-2_4-sell-side-bails\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NYCB -2.4% as sell-side bails</a></h4><ul>\n<li>New York Community Bank (NYSE:<a href=\"https://seekingalpha.com/symbol/NYCB\" title=\"New York Community Bancorp Inc.\">NYCB</a>) gets two more downgrades following this week's cancellation of its purchase of Astoria Financial.</li>\n<li>This morning, it's Raymond James cutting to Market Perform from Outperform, and FBR downgrading to Underperform from Market Perform.</li>\n<li>Shares <font color=\"red\">-2.4%</font> premarket</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231937\" data-linked=\"NYCB -2.4% as sell-side bails\" data-tweet=\"$NYCB - NYCB -2.4% as sell-side bails https://seekingalpha.com/news/3231937-nycbminus-2_4-sell-side-bails?source=tweet\" data-url=\"https://seekingalpha.com/news/3231937-nycbminus-2_4-sell-side-bails\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231934\" data-ts=\"1482327565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRUS\" target=\"_blank\">MRUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231934-merus-n-v-inks-collaboration-deal-incyte-shares-jump-61-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Merus N.V. inks collaboration deal with Incyte; shares jump 61% premarket</a></h4><ul>\n<li>Relatively recent IPO Merus N.V. (NASDAQ:<a href=\"https://seekingalpha.com/symbol/MRUS\" title=\"Merus\">MRUS</a>) rockets <font color=\"green\">61%</font> premarket on increase volume in response to its announcement of a collaboration agreement with Incyte (NASDAQ:<a href=\"https://seekingalpha.com/symbol/INCY\" title=\"Incyte Corporation\">INCY</a>) focused on the research, discovery and development of bispecific antibodies utilizing Merus' Biclonics technology platform. Incyte will have exclusive rights to as many 11 bispecific antibody research programs, including two of Merus' current preclinical immuno-oncology programs.</li>\n<li>Under the terms of the agreement, Incyte will pay Merus $120M upfront and purchase 3.2M ordinary Merus shares at $25.</li>\n<li>The companies have agreed to collaborate on up to 11 programs. For one current preclinical program, Merus will retain all development and commercialization rights in the U.S. while Incyte will have ex-U.S. rights. Following regulatory approval anywhere, each company will pay the other tiered royalties ranging from 6 - 10%.</li>\n<li>Merus has the option to co-fund two other programs while Incyte will fund the other eight. In the eight Incyte-funded programs, Merus will be eligible to receive up to $350M in milestones per program in addition to tiered royalties ranging from 6 - 10%.</li>\n<li>The transaction should close in Q1.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231934\" data-linked=\"Merus N.V. inks collaboration deal with Incyte; shares jump 61% premarket\" data-tweet=\"$MRUS $MRUS $INCY - Merus N.V. inks collaboration deal with Incyte; shares jump 61% premarket https://seekingalpha.com/news/3231934-merus-n-v-inks-collaboration-deal-incyte-shares-jump-61-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3231934-merus-n-v-inks-collaboration-deal-incyte-shares-jump-61-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231930\" data-ts=\"1482327087\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PAYX\" target=\"_blank\">PAYX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231930-paychex-beats-0_01-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Paychex beats by $0.01, misses on revenue</a></h4><ul>\n<li>Paychex (NASDAQ:<a href=\"https://seekingalpha.com/symbol/PAYX\" title=\"Paychex, Inc.\">PAYX</a>): FQ2 EPS of $0.56 <font color=\"green\">beats by $0.01</font>.</li>\n<li>Revenue of $771.4M (+6.8% Y/Y) <font color=\"red\">misses by $7.59M</font>.</li>\n<li>Shares <font color=\"green\">+1.3%</font> PM.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231930\" data-linked=\"Paychex beats by $0.01, misses on revenue\" data-tweet=\"$PAYX - Paychex beats by $0.01, misses on revenue https://seekingalpha.com/news/3231930-paychex-beats-0_01-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3231930-paychex-beats-0_01-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231925\" data-ts=\"1482326862\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATRS\" target=\"_blank\">ATRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231925-antares-pharma-files-u-s-marketing-application-for-drug-device-testosterone-combo-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Antares Pharma files U.S. marketing application for drug-device testosterone combo; shares ahead 5% premarket</a></h4><ul>\n<li>Antares Pharma (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ATRS\" title=\"Antares Pharma Inc.\">ATRS</a>) is up <font color=\"green\">5%</font> premarket, albeit on only 600 shares, in response to its announcement that it has submitted a New Drug Application (NDA) to the FDA seeking approval of QuickShot Testosterone, a drug-device combination product that delivers a subcutaneous dose of testosterone via an auto injector, for the treatment of men with low testosterone (hypogonadism).</li>\n<li>The company says it is the first product designed for the subcutaneous delivery of testosterone through a fine gauge needle.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231925\" data-linked=\"Antares Pharma files U.S. marketing application for drug-device testosterone combo; shares ahead 5% premarket\" data-tweet=\"$ATRS - Antares Pharma files U.S. marketing application for drug-device testosterone combo; shares ahead 5% premarket https://seekingalpha.com/news/3231925-antares-pharma-files-u-s-marketing-application-for-drug-device-testosterone-combo-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3231925-antares-pharma-files-u-s-marketing-application-for-drug-device-testosterone-combo-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231919\" data-ts=\"1482325909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXEL\" target=\"_blank\">EXEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231919-exelixis-amends-cabometyx-deal-transferring-canadian-rights-to-ipsen-shares-up-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exelixis amends Cabometyx deal transferring Canadian rights to Ipsen; shares up 2% premarket</a></h4><ul>\n<li>Exelixis (NASDAQ:<a href=\"https://seekingalpha.com/symbol/EXEL\" title=\"Exelixis, Inc.\">EXEL</a>) <a href=\"https://www.sec.gov/Archives/edgar/data/939767/000093976716000295/form8-kipsencanadaamendment.htm\" target=\"_blank\">transfers </a>its commercialization rights to CABOMETYX (cabozantinib) in Canada to partner Ipsen (<a href=\"https://seekingalpha.com/symbol/IPSEY\" title=\"Ipsen S.A. ADR\">OTCPK:IPSEY</a>)(<a href=\"https://seekingalpha.com/symbol/IPSEF\" title=\"Ipsen S.A.\">OTCPK:IPSEF</a>) while retaining the rights in the U.S. and Japan.</li>\n<li>In consideration of the move, Ipsen will pay Exelixis $10M upfront, up to $14M in regulatory milestones, up to CAD$26.5M in commercial milestones and tiered royalties from 22 - 26%.</li>\n<li>EXEL is ahead <font color=\"green\">2%</font> premarket on light volume.</li>\n<li>The companies inked their partnership in February.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3150626-exelixis-inks-cabozantinib-commercialization-deal-ipsen-valued-high-855m-shares-9-percent\" target=\"_blank\">Exelixis inks cabozantinib commercialization deal with Ipsen valued as high as $855M; shares up 9% after hours</a> (Feb. 29)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231919\" data-linked=\"Exelixis amends Cabometyx deal transferring Canadian rights to Ipsen; shares up 2% premarket\" data-tweet=\"$EXEL $EXEL $IPSEY - Exelixis amends Cabometyx deal transferring Canadian rights to Ipsen; shares up 2% premarket https://seekingalpha.com/news/3231919-exelixis-amends-cabometyx-deal-transferring-canadian-rights-to-ipsen-shares-up-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3231919-exelixis-amends-cabometyx-deal-transferring-canadian-rights-to-ipsen-shares-up-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231911\" data-ts=\"1482324848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CALA\" target=\"_blank\">CALA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231911-calithera-bio-up-20-premarket-on-collaboration-bristol-myers-in-kidney-cancer-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Calithera Bio up 20% premarket on collaboration with Bristol-Myers in kidney cancer study</a></h4><ul>\n<li>Calithera Biosciences (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CALA\" title=\"Calithera Biosciences\">CALA</a>) and Bristol-Myers Squibb (NYSE:<a href=\"https://seekingalpha.com/symbol/BMY\" title=\"Bristol-Myers Squibb Company\">BMY</a>) will collaborate on a clinical trial assessing the combination of Opdivo (nivolumab) and CB-839 in patients with clear cell renal cell carcinoma.</li>\n<li>\n<a href=\"http://www.calithera.com/programs/cb-839/\" target=\"_blank\">CB-839</a> is an orally administered inhibitor of an enzyme called glutaminase. It is designed to starve tumor cells of a protein called glutamine, a key nutrient. The rationale is that it may enhance the effects of checkpoint inhibitors and may reverse tumor resistance to checkpoint inhibitors by altering the immune-suppressive microenvironment and promoting an anti-tumor immune response. Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression.</li>\n<li>CALA is up <font color=\"green\">20%</font> premarket on average volume.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231911\" data-linked=\"Calithera Bio up 20% premarket on collaboration with Bristol-Myers in kidney cancer study\" data-tweet=\"$CALA $CALA $BMY - Calithera Bio up 20% premarket on collaboration with Bristol-Myers in kidney cancer study https://seekingalpha.com/news/3231911-calithera-bio-up-20-premarket-on-collaboration-bristol-myers-in-kidney-cancer-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3231911-calithera-bio-up-20-premarket-on-collaboration-bristol-myers-in-kidney-cancer-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231909\" data-ts=\"1482324647\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FL\" target=\"_blank\">FL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231909-foot-locker-on-watch-investors-eye-nke-and-finl-reports\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Foot Locker on watch as investors eye NKE and FINL reports</a></h4><ul> <li>Shares of Foot Locker (NYSE:<a href=\"https://seekingalpha.com/symbol/FL\" title=\"Foot Locker, Inc.\">FL</a>) are down in early trading after Finish Line disappointed with its earnings report and futures growth at Nike came in lower than anticipated.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3231813-nike-delivers-earnings-surprise\" target=\"_blank\">Nike delivers earnings surprise</a> (Dec. 20)</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3231867-nike-call-futures-orders-light-momentum-basketball\" target=\"_blank\">Nike call: Futures orders light, momentum in basketball</a> (Dec. 20)</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3231902-finish-line-crushed-posting-slow-sales-growth\" target=\"_blank\">Finish Line crushed after posting slow sales growth</a> (Dec. 21)</li> <li>FL <font color=\"red\">-2.13%</font> premarket to $74.00.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3231909\" data-linked=\"Foot Locker on watch as investors eye NKE and FINL reports\" data-tweet=\"$FL - Foot Locker on watch as investors eye NKE and FINL reports https://seekingalpha.com/news/3231909-foot-locker-on-watch-investors-eye-nke-and-finl-reports?source=tweet\" data-url=\"https://seekingalpha.com/news/3231909-foot-locker-on-watch-investors-eye-nke-and-finl-reports\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231907\" data-ts=\"1482323926\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WGO\" target=\"_blank\">WGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231907-towable-business-lifts-winnebago\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Towable business lifts Winnebago</a></h4><ul> <li>Winnebago (NYSE:<a href=\"https://seekingalpha.com/symbol/WGO\" title=\"Winnebago Industries, Inc.\">WGO</a>) reports a 44% increase in operating income during <a href=\"http://phx.corporate-ir.net/phoenix.zhtml?c=85260&amp;p=irol-newsArticle&amp;ID=2231096\" target=\"_blank\">FQ1</a> to $18.4M.</li> <li>Strong growth in the company\u2019s towable business helped to offset a dip in motorized revenue. Towable revenue was up 197% to $50.2M as the Grand Design acquisition kicked in.</li> <li>Winnebago ended the quarter with a debt to equity ratio of 86.1% and a current ratio of 2.1.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3231903-winnebago-eps-0_42\" target=\"_blank\">Winnebago EPS of $0.42</a> (Dec. 21)</li> <li>WGO <font color=\"green\">+4.84%</font> premarket to $39.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231907\" data-linked=\"Towable business lifts Winnebago\" data-tweet=\"$WGO - Towable business lifts Winnebago https://seekingalpha.com/news/3231907-towable-business-lifts-winnebago?source=tweet\" data-url=\"https://seekingalpha.com/news/3231907-towable-business-lifts-winnebago\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231905\" data-ts=\"1482323759\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MACK\" target=\"_blank\">MACK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231905-merrimack-bails-on-mid-stage-study-of-mmminus-302-in-breast-cancer-shares-down-30-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Merrimack bails on mid-stage study of MM-302 in breast cancer; shares down 30% premarket</a></h4><ul>\n<li>Merrimack Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/MACK\" title=\"Merrimack Pharmaceuticals\">MACK</a>) terminates its Phase 2 study, HERMIONE, assessing MM-302 in patients with HER2-positive metastatic breast cancer who were previously treated with Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine). It decided to end the trial after a recommendation by the independent Data and Safety Monitoring Board (DSMB) that it was unlikely to show a benefit over comparator treatments. A subsequent futility analysis confirmed DSMB's opinion.</li>\n<li>The company will provide further details next month.</li>\n<li>\n<a href=\"http://www.merrimack.com/molecule/MM-302\" target=\"_blank\">MM-302</a> is an antibody-drug conjugated liposomal doxorubicin that targets HER2-expressing cancer cells.</li>\n<li>Shares are down <font color=\"red\">30%</font> premarket on average volume.</li>\n<li>Related ticker: (<a href=\"https://seekingalpha.com/symbol/RHHBY\" title=\"Roche Holding Ltd ADR\">OTCQX:RHHBY</a>)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3231905\" data-linked=\"Merrimack bails on mid-stage study of MM-302 in breast cancer; shares down 30% premarket\" data-tweet=\"$MACK $MACK $RHHBY - Merrimack bails on mid-stage study of MM-302 in breast cancer; shares down 30% premarket https://seekingalpha.com/news/3231905-merrimack-bails-on-mid-stage-study-of-mmminus-302-in-breast-cancer-shares-down-30-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3231905-merrimack-bails-on-mid-stage-study-of-mmminus-302-in-breast-cancer-shares-down-30-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231904\" data-ts=\"1482323509\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAY\" target=\"_blank\">PLAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231904-suntrust-sees-dave-busters-rally-extending\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SunTrust sees Dave &amp; Buster&#39;s rally extending</a></h4><ul> <li>SunTrust initiates coverage on Dave &amp; Buster's Entertainment (NASDAQ:<a href=\"https://seekingalpha.com/symbol/PLAY\" title=\"Dave &amp; Buster's Entertainment, Inc.\">PLAY</a>) with a Buy rating.</li> <li>The investment firm sets a price target of <a href=\"https://www.marketbeat.com/stocks/NASDAQ/PLAY/\" target=\"_blank\">$68</a> on the family-friendly chain. The PT appears to be a Street high.</li> <li>Shares of D&amp;B cruised to a post-IPO high of $58.00 earlier this month</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3231904\" data-linked=\"SunTrust sees Dave &amp; Buster&#39;s rally extending\" data-tweet=\"$PLAY - SunTrust sees Dave &amp; Buster&#39;s rally extending https://seekingalpha.com/news/3231904-suntrust-sees-dave-busters-rally-extending?source=tweet\" data-url=\"https://seekingalpha.com/news/3231904-suntrust-sees-dave-busters-rally-extending\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3231902\" data-ts=\"1482322901\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FINL\" target=\"_blank\">FINL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3231902-finish-line-crushed-after-posting-slow-sales-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finish Line crushed after posting slow sales growth</a></h4><ul>     <li>Finish Line (NASDAQ:<a href=\"https://seekingalpha.com/symbol/FINL\" title=\"The Finish Line, Inc.\">FINL</a>) reports comparable-store sales rose 0.7% in FQ3 vs. +8% consensus.</li>     <li>Gross margin increased 370 bps to 26.7% of sales.</li>     <li>SG&amp;A expense rate fell back 40 bps to 32.1% of sales.</li>      <li>Merchandise inventory +5% Y/Y to $401.53M.</li>     <li>\"Steep declines in apparel and accessories offset a high-single digit footwear comp gain and a 33% sales increase in our Macy\u2019s business,\" notes CEO Sam Sato.</li>     <li>Looking ahead, Finish Line expects FY17 comparable-store sales growth to be flat to +1%. EPS of $1.24-$1.40 is seen vs. $1.53 consensus.</li> <li>FINL <font color=\"red\">-15.25%</font> premarket to $19.50.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3231902\" data-linked=\"Finish Line crushed after posting slow sales growth\" data-tweet=\"$FINL - Finish Line crushed after posting slow sales growth https://seekingalpha.com/news/3231902-finish-line-crushed-after-posting-slow-sales-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3231902-finish-line-crushed-after-posting-slow-sales-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":56,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}